Author(s)

Guoxiang Liu ¹, Zhichao Wang ², Xiaohui Zhang ³, Sreemoy Kanti Das ¹

Affiliation(s)

¹ Faculty of Pharmacy, Lincoln University College, Petaling Jaya, Selangor, Malaysia
² Department of Medicine, Lincoln University College, Petaling Jaya, Selangor, Malaysia
³ Department of Rehabilitation Medicine, Heilongjiang Nursing College, Harbin, Heilongjiang, China

Corresponding Author

Sreemoy Kanti Das

ABSTRACT

How to prove whether Huanglian Wendan Tang is effective in diabetes with non-alcoholic fatty liver disease? At present, there is a lack of large-scale clinical observation and research on the application effect of Huanglian Wendan Tang in diabetes patients with nonalcoholic fatty liver. The purpose of this study was to observe the effect of Huanglian Wendan Tang in patients with diabetes and non-alcoholic fatty liver disease. This article recruited a total of 60 cases that met the inclusion criteria, of which 30 patients received Huanglian Wendan Tang treatment (experimental group), and the other 30 patients received conventional treatment (control group). The experimental group patients took Huanglian Wendan Tang orally, three times a day, and received continuous treatment for four weeks. Two groups of patients underwent clinical examinations and evaluation of laboratory indicators before and after treatment. After several experimental tests, it was found that patients in the experimental group showed significant improvements after treatment. After taking Huanglian Wendan Tang continuously for one month, the blood sugar decreased from 12.85mmol/L to 8.6mmol/L, which can effectively lower the blood sugar in the patient's body.

KEYWORDS

Diabetes Study, Nonalcoholic Fatty Liver Disease, Huanglian Wendan Tang, Fasting Blood Glucose

CITE THIS PAPER

Guoxiang Liu, Zhichao Wang, Xiaohui Zhang, Sreemoy Kanti Das, Effect of Huanglian Wendan Tang on Diabetes Patients with Nonalcoholic Fatty Liver. MEDS Basic Medicine (2024) Vol. 2: 1-7. DOI: http://dx.doi.org/10.23977/medbm.2024.020101.

REFERENCES

[1] Wu Wenxia, Yang Jiewen, Li Yongbin, Wei Xinxin, Zhao Jiuzhun. Clinical experience of Chief Physician Platinum Shang in the treatment of type 2 diabetes combined with nonalcoholic fatty liver .Inner Mongolia Traditional Chinese Medicine, 2023, 42(2):22-25
[2] Li Xuexia, Chen Fang, Zhou Yu, Chen Gang, Wang Feng, Gao Liping.Effects of Sigliptin combined with metformin on myocardial injury and heart function in patients with type 2 diabetes combined with nonalcoholic fatty liver .Chinese contemporary Medicine,2023,30(3):79-82+86
[3] Qian Fangfang, Dai Meiqing, Zhao Li, Deng Xia, Yang Ling, Jia Jue, Wang Jifang, Wang Dong, Yuan Guoyue. Correlation analysis of serum alkaline phosphatase and type 2 diabetes combined with nonalcoholic fatty liver disease .Journal of Clinical Hepatobiliary Disease,2023,39(1):83-88
[4] Ma Xiaohui, Ji Pengfei, Zhang Xinle, Yang Hongyan. The relationship between serum vitamin D and liver fat content in patients with type 2 diabetes combined with nonalcoholic fatty liver .Journal of North Sichuan Medical College, 2023, 38(1):59-63
[5] Zhang Haichao, Wang Xiaoju, Wang Di, Yang Zhixia, Zhang Hongying. The relationship between Metrnl and Spexin expression levels and insulin resistance in patients with type 2 diabetes combined with nonalcoholic fatty liver disease. Marker immunoassay and clinical,2023,30(4):631-635
[6] Kramer J R, Natarajan Y, Dai J, et al. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease. Hepatology, 2022, 75(6): 1420-1428.
[7] Nobili V, Mantovani A, Cianfarani S, et al. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. Journal of hepatology, 2019, 71(4): 802-810.
[8] Athyros V G, Polyzos S A, Kountouras J, et al. Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block. Current vascular pharmacology, 2020, 18(2): 172-181.
[9] Arrese M, Barrera F, Triantafilo N, et al. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Review of Gastroenterology & Hepatology, 2019, 13(9): 849-866.
[10] Sung K C, Seo D C, Lee S J, et al. Non alcoholic fatty liver disease and risk of incident diabetes in subjects who are not obese. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29(5): 489-495.
[11] Ren S M, Mei L, Huang H, et al. Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease. Chinese Journal of Hepatology, 2019, 27(5): 369-375.
[12] Cho E E L, Ang C Z, Quek J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut, 2023, 72(11): 2138-2148.
[13] de Vries M, Westerink J, Kaasjager K H A H, et al. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. The Journal of Clinical Endocrinology & Metabolism, 2020, 105(12): 3842-3853.
[14] Lee B W, Lee Y, Park C Y, et al. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a position statement of the Fatty Liver Research Group of the Korean Diabetes Association. Diabetes & metabolism journal, 2020, 44(3): 382-401.
[15] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut, 2021, 70(5): 962-969.
[16] Musolino V, Gliozzi M, Bombardelli E, et al. The synergistic effect of Citrus bergamia and Cynara cardunculus extracts on vascular inflammation and oxidative stress in non-alcoholic fatty liver disease. Journal of Traditional and Complementary Medicine, 2020, 10(3): 268-274.
[17] Morrison A E, Zaccardi F, Khunti K, et al. Causality between non‐alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta‐analysis with bias analysis. Liver International, 2019, 39(3): 557-567.
[18] Matsuzaka T, Shimano H. New perspective on type 2 diabetes, dyslipidemia and non‐alcoholic fatty liver disease. Journal of diabetes investigation, 2020, 11(3): 532-534.
[19] Barata L, Feitosa M F, Bielak L F, et al. Insulin resistance exacerbates genetic predisposition to nonalcoholic fatty liver disease in individuals without diabetes. Hepatology communications, 2019, 3(7): 894-907.
[20] Lee Y, Cho Y, Lee B W, et al. Nonalcoholic fatty liver disease in diabetes. Part I: epidemiology and diagnosis. Diabetes & metabolism journal, 2019, 43(1): 31-45.

Sponsors, Associates, and Links

---

• MEDS Clinical Medicine
  
  
• Journal of Neurobiology and Genetics
  
  
• Medical Imaging and Nuclear Medicine
  
  
• Bacterial Genetics and Ecology
  
  
• Transactions on Cancer
  
  
• Journal of Biophysics and Ecology
  
  
• Journal of Animal Science and Veterinary
  
  
• Academic Journal of Biochemistry and Molecular Biology
  
  
• Transactions on Cell and Developmental Biology
  
  
• Rehabilitation Engineering & Assistive Technology
  
  
• Orthopaedics and Sports Medicine
  
  
• Hematology and Stem Cell
  
  
• Journal of Intelligent Informatics and Biomedical Engineering
  
  
• MEDS Stomatology
  
  
• MEDS Public Health and Preventive Medicine
  
  
• MEDS Chinese Medicine
  
  
• Journal of Enzyme Engineering
  
  
• Advances in Industrial Pharmacy and Pharmaceutical Sciences
  
  
• Bacteriology and Microbiology
  
  
• Advances in Physiology and Pathophysiology
  
  
• Journal of Vision and Ophthalmology
  
  
• Frontiers of Obstetrics and Gynecology
  
  
• Digestive Disease and Diabetes
  
  
• Advances in Immunology and Vaccines
  
  
• Nanomedicine and Drug Delivery
  
  
• Cardiology and Vascular System
  
  
• Pediatrics and Child Health
  
  
• Journal of Reproductive Medicine and Contraception
  
  
• Journal of Respiratory and Lung Disease
  
  
• Journal of Bioinformatics and Biomedicine